ReviewFrontiers in oncology2024
Altered lipid metabolism in APC-driven colorectal cancer: the potential for therapeutic intervention.
Review in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- ASF1A: A versatile histone chaperone bridging chromatin dynamics, disease mechanisms and clinical potential (Review).Experimental and therapeutic medicine · 2026Review
- Multi Omics Integration in Colorectal Cancer: From Molecular Insights to Precision Oncology.Cancers · 2026Review
- Lipid metabolism as a central driver of immune remodeling and therapeutic vulnerability in metastatic colorectal cancer.Lipids in health and disease · 2026Review
- Membrane Curvature and Cancer: Mechanisms, Implications, and Therapeutic Perspectives.Cancers · 2026Review
- CPNE3 promotes colorectal cancer progression by regulating KIF4-mediated autophagy.Journal of gastrointestinal oncology · 2026Article
- Fucoidan induces ferroptosis in colorectal cancer cells by regulating the SLC7A11/GPX4 signaling pathway and modulating metabolic pathways.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Common oncogenic mutations in colorectal cancer: drivers of carcinogenesis and potential therapeutic targets.Frontiers in pharmacology · 2026Review
- Targeted plasma lipidomics in non-metastatic colorectal cancer, metastatic colorectal cancer, and healthy controls: an exploratory matched-triplet study.Frontiers in oncology · 2026Article
- Article
- Recent advances and challenges in colorectal cancer: From molecular research to treatment.World journal of gastroenterology · 2025Review
- Lipid Metabolism and Relevance to Chronic Disease.Nutrients · 2025Article
- Signature Gene Mutations in Colorectal Cancer: Potential Neoantigens for Cancer Vaccines.International journal of molecular sciences · 2025Review
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Altered lipid metabolism is a well-recognized feature of solid cancers, including colorectal cancer. In colorectal cancer, upregulation of lipid metabolism contributes to initiation, progression, and metastasis; thus, aberrant lipid metabolism contributes to a poor patient outcome. The inactivating mutation of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.